Medline, Inc. MDLN Tax Credit Carryforward Valuation Allowance
Tax Credit Carryforward Valuation Allowance at other companies
Other financials
Where this comes from
Reported directly by Medline, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsValuationAllowance.
The source filing: Medline, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0002046386-26-000051
In connection with the Reorganization and the IPO, the Company also entered into a TRA with certain pre-IPO owners. See Note 7 —Tax Receivable Agreement for additional information. During the six months ended June 27, 2026, the Company recorded additional TRA liability of $862 million and a deferred tax asset of $391 million (net of a $209 million valuation allowance), principally due to the effects of the May 2026 Resale Offering, the March 2026 Resale Offering, and other exchanges of Incentive Units and Common Units.
Item 1 - Financial Statements
FAQ
- What is Medline, Inc.'s tax credit carryforward valuation allowance?
- Medline, Inc. (MDLN) reported tax credit carryforward valuation allowance of $209M in Q2 2026.
- What does tax credit carryforward valuation allowance mean?
- This is a contra-asset account that reduces the carrying value of tax credit carryforwards when it is more likely than not that some or all of the credits will not be realized. It reflects management's assessment of the company's ability to generate sufficient future taxable income. A high allowance suggests uncertainty regarding the realization of tax benefits.
Ask your AI about Medline, Inc.'s tax credit carryforward valuation allowance.
Connect your AI assistant and compare it to peers, right in your chat.
